Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of CML patients achieving deep and sustained molecul...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Loscocco, Federica, Visani, Giuseppe, Ruzzo, Annamaria, Bagaloni, Irene, Fuligni, Fabio, Galimberti, Sara, Di Paolo, Antonello, Stagno, Fabio, Pregno, Patrizia, Annunziata, Mario, Gozzini, Antonella, Barulli, Sara, Gabucci, Elisa, Magnani, Mauro, Isidori, Alessandro
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155509/
https://ncbi.nlm.nih.gov/pubmed/34055641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.672287
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares